Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination

被引:8
作者
Keeshan, Alexa [1 ,2 ]
Galipeau, Yannick [3 ]
Heiskanen, Aliisa [1 ,2 ]
Collins, Erin [2 ]
Mccluskie, Pauline S. [4 ]
Arnold, Corey [4 ]
Saginur, Raphael [5 ]
Booth, Ronald [6 ]
Little, Julian [2 ]
Mcguinty, Michaeline [7 ]
Buchan, C. Arianne [1 ,7 ,8 ]
Crawley, Anglea [8 ,9 ,10 ]
Langlois, Marc-Andre [10 ,11 ]
Cooper, Curtis [1 ,8 ,10 ,12 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa, ON, Canada
[2] Univ Ottawa, Sch Epidemiol & Publ Hlth, Fac Med, Ottawa, ON, Canada
[3] Univ Ottawa, Dept Biochem, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada
[5] Ottawa Hosp, Dept Med, Ottawa, ON, Canada
[6] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada
[7] Ottawa Hosp, Dept Med, Div Infect Dis, Ottawa, ON, Canada
[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[9] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON, Canada
[10] Coronavirus Variants Rapid Response Network, Ottawa, ON, Canada
[11] Univ Ottawa, Biochem Microbiol & Immunol, Ottawa, ON, Canada
[12] Ottawa Hosp Res Inst, Clin Epidemiol Program, Div Infect Dis, Ottawa, ON, Canada
基金
加拿大健康研究院;
关键词
COVID-19; immunology; safety;
D O I
10.1136/bmjopen-2023-077714
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundPredictors of COVID-19 vaccine immunogenicity and the influence of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection require elucidation.MethodsStop the Spread Ottawa is a prospective cohort of individuals at-risk for or who have been infected with SARS-CoV-2, initially enrolled for 10 months beginning October 2020. This cohort was enriched for public-facing workers. This analysis focuses on safety and immunogenicity of the initial two doses of COVID-19 vaccine.ResultsPost-vaccination data with blood specimens were available for 930 participants. 22.8% were SARS-CoV2 infected prior to the first vaccine dose. Cohort characteristics include: median age 44 (IQR: 22-56), 66.6% women, 89.0% white, 83.2% employed. 38.1% reported two or more comorbidities and 30.8% reported immune compromising condition(s). Over 95% had detectable IgG levels against the spike and receptor binding domain (RBD) 3 months post second vaccine dose. By multivariable analysis, increasing age and high-level immune compromise predicted diminishing IgG spike and RBD titres at month 3 post second dose. IgG spike and RBD titres were higher immediately post vaccination in those with SARS-CoV-2 infection prior to first vaccination and spike titres were higher at 6 months in those with wider time intervals between dose 1 and 2. IgG spike and RBD titres and neutralisation were generally similar by sex, weight and whether receiving homogeneous or heterogeneous combinations of vaccines. Common symptoms post dose 1 vaccine included fatigue (64.7%), injection site pain (47.5%), headache (27.2%), fever/chills (26.2%) and body aches (25.3%). These symptoms were similar with subsequent doses.ConclusionThe initial two COVID-19 vaccine doses are safe, well-tolerated and highly immunogenic across a broad spectrum of vaccine recipients including those working in public facing environments.
引用
收藏
页数:14
相关论文
共 27 条
[1]   Duration of immunity following full vaccination against SARS-CoV-2: a systematic review [J].
Addo, Isaac Yeboah ;
Dadzie, Frederick Asankom ;
Okeke, Sylvester Reuben ;
Boadi, Caleb ;
Boadu, Elijah Frimpong .
ARCHIVES OF PUBLIC HEALTH, 2022, 80 (01)
[2]   Covid-19 vaccination in pregnancy [J].
Badell, Martina L. ;
Dude, Carolynn M. ;
Rasmussen, Sonja A. ;
Jamieson, Denise J. .
BMJ-BRITISH MEDICAL JOURNAL, 2022, 378
[3]   Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection [J].
Bates, Timothy A. ;
McBride, Savannah K. ;
Winders, Bradie ;
Schoen, Devin ;
Trautmann, Lydie ;
Curlin, Marcel E. ;
Tafesse, Fikadu G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (02) :179-181
[4]   Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study [J].
Ben Fredj, Sihem ;
Ghammem, Rim ;
Zammit, Nawel ;
Maatouk, Amani ;
Haddad, Nihel ;
Haddad, Nouha ;
Kachroudi, Manel ;
Rebai, Senda ;
Laadhari, Hafsia ;
Ghodhbani, Mohamed Mizouni ;
Maatoug, Jihen ;
Ghannem, Hassen .
BMC INFECTIOUS DISEASES, 2022, 22 (01)
[5]   Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis [J].
Booth, Adam ;
Reed, Angus Bruno ;
Ponzo, Sonia ;
Yassaee, Arrash ;
Aral, Mert ;
Plans, David ;
Labrique, Alain ;
Mohan, Diwakar .
PLOS ONE, 2021, 16 (03)
[6]   Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults [J].
Brockman, Mark A. ;
Mwimanzi, Francis ;
Lapointe, Hope R. ;
Sang, Yurou ;
Agafitei, Olga ;
Cheung, Peter K. ;
Ennis, Siobhan ;
Ng, Kurtis ;
Basra, Simran ;
Lim, Li Yi ;
Yaseen, Fatima ;
Young, Landon ;
Umviligihozo, Gisele ;
Omondi, F. Harrison ;
Kalikawe, Rebecca ;
Burns, Laura ;
Brumme, Chanson J. ;
Leung, Victor ;
Montaner, Julio S. G. ;
Holmes, Daniel ;
DeMarco, Mari L. ;
Simons, Janet ;
Pantophlet, Ralph ;
Niikura, Masahiro ;
Romney, Marc G. ;
Brumme, Zabrina L. .
JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (07) :1129-1140
[7]  
Centers for Disease Control and Prevention (CDC), 2023, Safety of COVID-19 vaccines
[8]   Cohort profile: Stop the Spread Ottawa (SSO)-a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination [J].
Collins, Erin ;
Galipeau, Yannick ;
Arnold, Corey ;
Bosveld, Cameron ;
Heiskanen, Aliisa ;
Keeshan, Alexa ;
Nakka, Kiran ;
Shir-Mohammadi, Khatereh ;
St-Denis-Bissonnette, Frederic ;
Tamblyn, Laura ;
Vranjkovic, Agatha ;
Wood, Leah C. ;
Booth, Ronald ;
Buchan, C. Arianne ;
Crawley, Angela M. ;
Little, Julian ;
McGuinty, Michaeline ;
Saginur, Raphael ;
Langlois, Marc-Andre ;
Cooper, Curtis L. .
BMJ OPEN, 2022, 12 (09)
[9]   A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination [J].
Colwill, Karen ;
Galipeau, Yannick ;
Stuible, Matthew ;
Gervais, Christian ;
Arnold, Corey ;
Rathod, Bhavisha ;
Abe, Kento T. ;
Wang, Jenny H. ;
Pasculescu, Adrian ;
Maltseva, Mariam ;
Rocheleau, Lynda ;
Pelchat, Martin ;
Fazel-Zarandi, Mahya ;
Iskilova, Mariam ;
Barrios-Rodiles, Miriam ;
Bennett, Linda ;
Yau, Kevin ;
Cholette, Francois ;
Mesa, Christine ;
Li, Angel X. ;
Paterson, Aimee ;
Hladunewich, Michelle A. ;
Goodwin, Pamela J. ;
Wrana, Jeffrey L. ;
Drews, Steven J. ;
Mubareka, Samira ;
McGeer, Allison J. ;
Kim, John ;
Langlois, Marc-Andre ;
Gingras, Anne-Claude ;
Durocher, Yves .
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022, 11 (03)
[10]  
Division of Population Health-National Center for Chronic Disease Prevention and Health Promotion-Centers for Disease Control and Prevention, 2022, Alcohol use and your health: U.S Department of health & human services